RU2728867C2 - Способ совместного кондиционирования и хемоселекции за один цикл - Google Patents

Способ совместного кондиционирования и хемоселекции за один цикл Download PDF

Info

Publication number
RU2728867C2
RU2728867C2 RU2017104621A RU2017104621A RU2728867C2 RU 2728867 C2 RU2728867 C2 RU 2728867C2 RU 2017104621 A RU2017104621 A RU 2017104621A RU 2017104621 A RU2017104621 A RU 2017104621A RU 2728867 C2 RU2728867 C2 RU 2728867C2
Authority
RU
Russia
Prior art keywords
hprt
subject
deficient
transplantation
cells
Prior art date
Application number
RU2017104621A
Other languages
English (en)
Russian (ru)
Other versions
RU2017104621A3 (enExample
RU2017104621A (ru
Inventor
Нориюки КАСАХАРА
Роберт Х. ШИСТЛ
Катрин ХАКЕ
Акош ШАКМАРИ
Гай М. КРУКС
Original Assignee
Де Реджентс Оф Де Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Де Реджентс Оф Де Юниверсити Оф Калифорния filed Critical Де Реджентс Оф Де Юниверсити Оф Калифорния
Publication of RU2017104621A publication Critical patent/RU2017104621A/ru
Publication of RU2017104621A3 publication Critical patent/RU2017104621A3/ru
Application granted granted Critical
Publication of RU2728867C2 publication Critical patent/RU2728867C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017104621A 2011-04-20 2012-04-20 Способ совместного кондиционирования и хемоселекции за один цикл RU2728867C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477440P 2011-04-20 2011-04-20
US61/477,440 2011-04-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2013151632A Division RU2611396C2 (ru) 2011-04-20 2012-04-20 Способ совместного кондиционирования и хемоселекции за один цикл

Publications (3)

Publication Number Publication Date
RU2017104621A RU2017104621A (ru) 2018-08-15
RU2017104621A3 RU2017104621A3 (enExample) 2020-06-04
RU2728867C2 true RU2728867C2 (ru) 2020-07-31

Family

ID=47041955

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017104621A RU2728867C2 (ru) 2011-04-20 2012-04-20 Способ совместного кондиционирования и хемоселекции за один цикл
RU2013151632A RU2611396C2 (ru) 2011-04-20 2012-04-20 Способ совместного кондиционирования и хемоселекции за один цикл

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013151632A RU2611396C2 (ru) 2011-04-20 2012-04-20 Способ совместного кондиционирования и хемоселекции за один цикл

Country Status (11)

Country Link
US (1) US9439928B2 (enExample)
EP (3) EP3384912B1 (enExample)
JP (4) JP5997257B2 (enExample)
AU (3) AU2012245269B2 (enExample)
CA (1) CA2861440C (enExample)
DK (1) DK2699247T3 (enExample)
ES (1) ES2672693T3 (enExample)
PL (1) PL2699247T3 (enExample)
RU (2) RU2728867C2 (enExample)
TR (1) TR201808037T4 (enExample)
WO (1) WO2012145723A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9682106B2 (en) * 2011-04-20 2017-06-20 The Regents Of The University Of California Method for combined conditioning and chemoselection in a single cycle
RU2728867C2 (ru) * 2011-04-20 2020-07-31 Де Реджентс Оф Де Юниверсити Оф Калифорния Способ совместного кондиционирования и хемоселекции за один цикл
US20170209447A1 (en) * 2014-08-07 2017-07-27 Nitor Therapeutics Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant
US20180140606A1 (en) * 2016-11-18 2018-05-24 Calimmune, Inc. In Vivo Chemoselection with Low Dose Thioguanine
JP6783674B2 (ja) 2017-01-20 2020-11-11 株式会社日立ハイテク 自動分析装置、自動分析装置における廃液方法、及び、三方電磁弁
EP4190339B1 (en) 2017-07-18 2025-07-02 CSL Behring Gene Therapy, Inc. A modulatable switch for selection of donor modified cells
BR112020001059A2 (pt) * 2017-07-18 2020-07-14 Calimmune, Inc. composições e métodos para o tratamento de beta-hemoglobinopatias
JP2020536554A (ja) * 2017-10-09 2020-12-17 ストワーズ インスティテュート フォー メディカル リサーチ 細胞集団を増大させるための方法および組成物
JP2022514954A (ja) * 2018-12-23 2022-02-16 シーエスエル・ベーリング・エルエルシー キルスイッチを有するドナーｔ細胞
EP3897745A1 (en) * 2018-12-23 2021-10-27 CSL Behring LLC Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032003A1 (en) * 2000-02-02 2003-02-13 Schiestl Robert H. In vivo selection
US20030073649A1 (en) * 2001-10-12 2003-04-17 Dimartino Jorge Composition and method for treating graft-versus-host disease
RU2216336C2 (ru) * 1999-02-24 2003-11-20 Реньюрон Лимитед Трансплантация гемопоэтических клеток
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965126A (en) 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
WO1997043900A1 (en) 1996-05-24 1997-11-27 The President And Fellows Of Harvard College In vivo selection
AU7605796A (en) 1996-11-04 1998-05-29 Saint Jude Children's Research Hospital (in vivo) selection of primitive hematopoietic cells
ATE439137T1 (de) * 1997-11-14 2009-08-15 Gen Hospital Corp Behandlung von hämatologischen störungen
CA2428721A1 (en) * 2000-11-14 2002-05-23 The General Hospital Corporation Blockade of t cell migration into epithelial gvhd target tissues
RU2728867C2 (ru) * 2011-04-20 2020-07-31 Де Реджентс Оф Де Юниверсити Оф Калифорния Способ совместного кондиционирования и хемоселекции за один цикл

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2216336C2 (ru) * 1999-02-24 2003-11-20 Реньюрон Лимитед Трансплантация гемопоэтических клеток
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US20030032003A1 (en) * 2000-02-02 2003-02-13 Schiestl Robert H. In vivo selection
US20030073649A1 (en) * 2001-10-12 2003-04-17 Dimartino Jorge Composition and method for treating graft-versus-host disease

Also Published As

Publication number Publication date
AU2012245269B2 (en) 2016-09-29
CA2861440C (en) 2022-11-15
AU2016259368B2 (en) 2017-12-14
DK2699247T3 (en) 2018-06-14
JP2018044007A (ja) 2018-03-22
JP6799117B2 (ja) 2020-12-09
AU2012245269A1 (en) 2013-12-05
PL2699247T3 (pl) 2018-09-28
JP2017008090A (ja) 2017-01-12
RU2017104621A3 (enExample) 2020-06-04
JP5997257B2 (ja) 2016-09-28
AU2018200967A1 (en) 2018-03-01
US9439928B2 (en) 2016-09-13
EP3799876A1 (en) 2021-04-07
JP6560332B2 (ja) 2019-08-14
RU2611396C2 (ru) 2017-02-21
AU2016259368A1 (en) 2016-12-08
RU2013151632A (ru) 2015-05-27
EP2699247A4 (en) 2014-11-19
RU2017104621A (ru) 2018-08-15
CA2861440A1 (en) 2012-10-26
EP3384912A1 (en) 2018-10-10
AU2018200967B2 (en) 2019-08-15
JP6266716B2 (ja) 2018-01-24
JP2019199476A (ja) 2019-11-21
EP3384912B1 (en) 2020-11-11
WO2012145723A1 (en) 2012-10-26
EP2699247A1 (en) 2014-02-26
ES2672693T3 (es) 2018-06-15
TR201808037T4 (tr) 2018-06-21
JP2014512391A (ja) 2014-05-22
US20140154225A1 (en) 2014-06-05
HK1256048A1 (en) 2019-09-13
EP2699247B1 (en) 2018-03-07

Similar Documents

Publication Publication Date Title
AU2018200967B2 (en) Method for combined conditioning and chemoselection in a single cycle
EP4190339B1 (en) A modulatable switch for selection of donor modified cells
Von Vietinghoff et al. Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 production
Chu et al. Basic and clinical pharmacology
US11607427B2 (en) Method for chemoselection
Hacke et al. Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow
CA2672716C (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
HK1256048B (en) Method for combined conditioning and chemoselection in a single cycle
US20240374569A1 (en) Hdac3 inhibitors for the treatment of langerhans cell histiocytosis and langerhans cell sarcoma
Can et al. Invasive pulmonary aspergillosis after liver transplantation: rapid and complete response to combined and sequential antifungal therapy
Fooks Targeting Eukaryotic Initiation Factor 4A to Improve Response to Chemotherapy in Acute Myeloid Leukemia
Moore Bone Marrow Transplantation in Leukemia